Lucileter 240 mg Tablet is an antiviral medication containing letermovir as its active ingredient. It belongs to the pharmacological class of antiviral agents and is specifically classified under cytomegalovirus (CMV) DNA terminase inhibitors. Lucileter 240 mg Tablet is primarily used to prevent cytomegalovirus (CMV) infection in patients who have recently undergone an allogeneic hematopoietic stem cell transplant (HSCT) and are at a higher risk of CMV reactivation.

Lucileter 240 mg Tablet works by inhibiting the CMV DNA terminase complex, which is crucial for viral replication. It is typically prescribed for CMV-seropositive adult patients post-transplant to reduce the likelihood of viral complications. However, the medication is not a treatment for existing CMV infections.

Patients taking this medication should follow strict safety precautions. It is contraindicated in individuals with known hypersensitivity to letermovir or any of its excipients. Additionally, it is not recommended for use with certain medications due to serious drug interactions. Healthcare professionals advise caution in pregnant or breastfeeding women, individuals with liver impairment, and those consuming alcohol.

Lucileter 240 mg Tablet is FDA-approved for the prevention of cytomegalovirus (CMV) infection in adult patients who:

• Have undergone allogeneic hematopoietic stem cell transplantation (HSCT).
• Are CMV-seropositive, meaning they have previously been exposed to the virus.

This medication is used prophylactically and should not be used to treat an active CMV infection.

Lucileter 240 mg Tablet functions by blocking the CMV DNA terminase complex, a key component required for viral replication. Unlike conventional antiviral drugs that target DNA polymerase, this medication disrupts viral DNA processing and packaging, ultimately preventing the virus from multiplying and spreading in the body.

By stopping CMV replication early in the process, this drug significantly lowers the risk of CMV disease in transplant recipients. The unique mechanism of action makes it highly effective while reducing the likelihood of cross-resistance seen with other CMV treatments. Due to its targeted action, it is well tolerated with a lower risk of severe toxicity compared to older antiviral medications.

The usual recommended dosage of Lucileter 240 mg Tablet for CMV prophylaxis is 480 mg once daily. However, if taken in combination with cyclosporine, the dose is reduced to 240 mg daily to prevent excessive drug levels. This medication is available in oral tablets and intravenous (IV) infusion forms. Oral tablets should be swallowed whole with or without food, while the IV infusion must be administered under medical supervision to ensure proper dosing and monitoring.

Common:

• Nausea
• Fatigue
• Headache
• Diarrhea
• Abdominal pain

Serious:

• Irregular heartbeat
• Swelling in legs or feet
• Unexplained bleeding or bruising
• Severe allergic reactions (rash, breathing difficulty)

Serious drug interactions can alter the effectiveness of the Lucileter 240 mg tablet or increase the risk of side effects. Patients should inform their doctor about all medications, including herbal and over-the-counter drugs, before starting this medication.

Notable Drug Interactions:

Immunosuppressants (e.g., Cyclosporine, Tacrolimus, Sirolimus): Letermovir can increase blood levels of these drugs, requiring dose adjustments.

Statins (e.g., Simvastatin, Atorvastatin): Increased risk of myopathy or rhabdomyolysis when taken together. Avoid co-administration or monitor closely.

Anticonvulsants (e.g., Phenytoin, Carbamazepine): May reduce Lucileter 240 mg Tablet effectiveness, requiring alternative options.

Rifampin and St. John’s Wort: These reduce drug efficacy and should be avoided.

Oral Contraceptives: Letermovir may lower the effectiveness of hormonal birth control, necessitating additional contraceptive methods.

Always consult a doctor before combining this medication with others.

• Keep the Lucileter 240 mg tablet at room temperature (20-25°C), away from moisture and direct sunlight.
• Do not double-dose.
• Seek immediate medical attention if an overdose occurs. Symptoms may include severe nausea or irregular heartbeat.

Patients prescribed the Lucileter 240 mg tablet should take it regularly to prevent CMV-related complications post-transplant. Always inform your doctor of any medications or supplements being taken to prevent harmful interactions. Missing doses can reduce the effectiveness of CMV prevention. Additionally, regular liver function tests may be required in certain patients.